非小细胞肺癌中表皮生长因子受体(EGFR)复合突变与EGFR酪氨酸激酶抑制剂治疗敏感性研究  

Correlation between epidermal growth factor receptor( EGFR ) mutations and EGFR-tyrosine inhibitors therapy sensibility in non-small cell lung cancer

作　　者：黄珊[1] 刘迪[1] HUANG Shan;LIU Di(Department of Oncology, Sichuan Provincial People＇ s Hospital, Chengdu 610071, China)

机构地区：[1]四川省人民医院肿瘤科,成都610071

出　　处：《中国临床药理学杂志》2018年第10期1144-1146,1150,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察非小细胞肺癌表皮生长因子受体(EGFR)复合突变与EGFR酪氨酸激酶抑制剂(EGFR-TKI)临床敏感性的关系,为含有EGFR突变的非小细胞肺癌患者EGFR-TKI治疗提供依据。方法回顾性分析95例EGFR突变且用EGFR-TKI治疗的非小细胞肺癌患者的病历资料,患者口服EGFR-TKI直至疾病进展或者不能耐受严重药物不良反应,并进行手术治疗。比较患者EGFR基因突变类型、患者术后的生存情况及不同类型EGFR-TKI的治疗效果。结果在95例EGFR突变的非小细胞肺癌患者中,EGFR-TKI敏感型突变21号外显子和19号外显子突变分别为31.58%和36.84%,EGFR复合突变比例为18.95%。19号外显子缺失突变组和21号外显子L858R点突变的疾病控制率分别为83.87%和75.00%,而复合突变经TKI治疗后疾病控制率为100.00%。结论大部分含有EGFR-TKI敏感性的EGFR突变与非典型的EGFR突变复合后都对EGFR-TKI敏感,这类患者疾病控制率较高。Objective To investigate the relationship between epidermal growth factor receptor(EGFR） mutation and the clinical sensitivity of EGFR tyrosine kinase inhibitor(EGFR-TKI） in non-small cell lung cancer,and to provide basis for the EGFR-TKI therapy in patients with EGFR mutation of non-small cell lung cancer. Methods The clinical data of 95 patients with EGFR mutation of non-small cell lung cancer treated with EGFR-TKI were retrospectively analyzed. Patients were orally given EGFR-TKI until the disease progressed or was unable to tolerate the serious adverse drug reactions and surgically treated. The type of EGFR gene mutation,the postoperative survival of patients and the therapeutic effect of different types of EGFR-TKI were compared.Results In 95 patients with EGFR mutation of non-small cell lung cancer,EGFR-TKI sensitive mutations in exon 21 and exon 19 were 31. 58%and 36. 84%,and EGFR recombination mutation rate was 18. 94%. The disease control rates of exon 19 deletion mutation and exon 21 L858 R point mutation were 83. 87% and 75. 00%,while the control rate of the compound mutation after TKI treatment was 100. 00%. Conclusion Most EGFR-TKI-sensitive EGFR mutations are attributed to EGFR-TKI after combination with atypical EGFR mutations,and have a high disease control rate.

关 键 词：上皮生长因子受体 非小细胞肺癌 酪氨酸激酶抑制药 

分 类 号：R979.1[医药卫生—药品]